Jpmorgan Chase & CO Blueprint Medicines Corp Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,155,634 shares of BPMC stock, worth $102 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,155,634
Previous 1,222,052
5.43%
Holding current value
$102 Million
Previous $113 Million
10.79%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding BPMC
# of Institutions
380Shares Held
65.9MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$599 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$588 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$502 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA4.28MShares$379 Million0.07% of portfolio
-
State Street Corp Boston, MA2.5MShares$221 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.28B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...